Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development and validation of a machine learning-based prediction model for hepatorenal syndrome in liver cirrhosis patients using MIMIC-IV and eICU databases.
Sci Rep
January 2025
Department of Gastrointestinal Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People's Republic of China.
Hepatorenal syndrome (HRS) is a key contributor to poor prognosis in liver cirrhosis. This study aims to leverage the database to build a predictive model for early identification of high-risk patients. From two sizable public databases, we retrieved pertinent information about the cirrhosis patients' therapies, comorbidities, laboratory results, and demographics.
View Article and Find Full Text PDFAssociation between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017-2018.
BMC Gastroenterol
January 2025
Gastroenterology Department, Longyan First Hospital, No. 105 Jiuyi North Road, Xinluo District, Longyan, 364300, Fujian, China.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is increasingly prevalent, and systemic inflammation markers may play a role in its pathogenesis. This study aimed to investigate the relationship between neutrophil-albumin ratio (NAR) and MAFLD.
Methods: This population-based study was performed using data from NHANES 2017-2018 and included 4526 individuals with a median age of 44 years old, and the males account for 46.
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.
Lancet Haematol
January 2025
National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China. Electronic address:
Background: Spleen tyrosine kinase inhibitors are potential treatment options for warm autoimmune haemolytic anaemia. This study aimed to assess the preliminary efficacy and safety of sovleplenib-an oral spleen tyrosine kinase inhibitor-in patients with warm autoimmune haemolytic anaemia in China. Here we report on the phase 2 results.
View Article and Find Full Text PDFAdjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Article Synopsis
- Early neurological deterioration (END) is linked to poor outcomes in acute ischemic stroke (AIS), and the study investigates how the drug evolocumab can help prevent this condition by lowering LDL cholesterol levels.
- The research was a clinical trial with AIS patients divided into two groups: one receiving evolocumab combined with atorvastatin and the other receiving atorvastatin alone, assessing outcomes like END rates and inflammatory markers over 7 days.
- Results showed that the combination therapy group had significantly lower rates of END (13.2% vs. 24.3%) and a much higher LDL cholesterol target achievement rate (74.3% vs. 14.7%), indicating the effectiveness of evolocumab in this context.
exon 20 insertion mutation and exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population.
Transl Lung Cancer Res
November 2024
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Background: Epidermal growth factor receptor () and mesenchymal-epithelial transition () gene mutations are well established in the pathogenesis of non-small cell lung cancer (NSCLC). However, there is limited understanding about the impact of rare variants, such as exon 20 insertion mutation (ex20ins) and exon 14 skipping mutation (ex14) in the Chinese population even though targeted therapies have been approved in China. We conducted a scoping review to assess the current available evidence of these two mutations in NSCLC in the Chinese population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!